Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas

被引:19
作者
Mao, Rui [1 ,2 ]
Li, Kan [3 ]
Cai, Jian-Qiang [1 ]
Luo, Sheng [4 ]
Turner, Megan [5 ]
Blazer, Dan, III [5 ]
Zhao, Hong [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Hepatobiliary Surg, Mol Oncol Lab,Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China
[2] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA
[3] Merck & Co Inc, Merck Res Lab, N Wales, PA USA
[4] Duke Univ, Dept Biostat & Bioinformat, Med Ctr, Durham, NC USA
[5] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
基金
中国国家自然科学基金;
关键词
adjuvant chemotherapy; colon and rectum; national cancer database; poorly differentiated neuroendocrine carcinomas; CONSENSUS GUIDELINES; SENSITIVITY-ANALYSIS; PROGNOSTIC-FACTORS; G3; MANAGEMENT; PANCREAS; CANCER;
D O I
10.1097/SLA.0000000000003562
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: The aim of this study was to determine whether adjuvant chemotherapy (AC) provides a survival benefit in patients with nonmetastatic poorly differentiated colorectal neuroendocrine carcinomas (CRNECs) following resection. Background: There is little evidence to support the association between use of AC and improved overall survival (OS) in patients with CRNECs. Methods: Patients with resected non-metastatic CRNECs were identified in the National Cancer Database (2004-2014). Inverse probability of treatment weighting (IPTW) method was used to reduce the selection bias. IPTW-adjusted Kaplan-Meier curves and Cox proportional hazards models were used to compare OS of patients in different treatment groups. Results: A total of 806 patients diagnosed between 2004 and 2014 met the study entry criteria. Of these, 394 patients (48.9%) received AC. IPTW-adjusted Kaplan-Meier curves showed that median OS was significantly longer for AC versus observation [57.4 (interquartile range, IQR, 14.8-153.8) vs 38.2 (IQR, 10.4-125.4) months; P = 0.007]. In IPTW-adjusted Cox proportional hazards regression analysis, AC was associated with a significant OS benefit [hazard ratio (HR) = 0.73, 95% confidence interval (CI) 0.64-0.84; P < 0.001]. The results were consistent across subgroups stratified by pathologic T stage, pathologic N stage, and surgical margin status. Subgroup analysis according to tumor location demonstrated improved OS in the adjuvant therapy cohort among patients with left-sided neuroendocrine carcinomas (HR, 0.55; 95% CI, 0.44-0.68), but not in those with right-sided disease (HR, 0.89; 95% CI, 0.74-1.07). Conclusions: Patients with nonmetastatic CRNECs may derive survival benefit from AC. These findings support current guidelines recommending AC in patients with poorly differentiated neuroendocrine carcinomas in the colon and rectum. Efforts in education and adherence to national guidelines for NECs are needed.
引用
收藏
页码:E126 / E133
页数:8
相关论文
共 35 条
[1]   Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature [J].
Baran, Burcin ;
Ozupek, Nazli Mert ;
Tetik, Nihal Yerli ;
Acar, Emine ;
Bekcioglu, Omer ;
Baskin, Yasemin .
GASTROENTEROLOGY RESEARCH, 2018, 11 (04) :264-273
[2]   Opportunity lost: Adjuvant chemotherapy in patients with stage III colon cancer remains underused [J].
Becerra, Adan Z. ;
Probst, Christian P. ;
Tejani, Mohamedtalti A. ;
Aquina, Christopher T. ;
Gonzalez, Maynor G. ;
Hensley, Bradley J. ;
Noyes, Katia ;
Monson, John R. T. ;
Fleming, Fergal J. .
SURGERY, 2015, 158 (03) :692-699
[3]   Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies [J].
Boeckx, N. ;
Koukakis, R. ;
de Beeck, K. Op ;
Rolfo, C. ;
Van Camp, G. ;
Siena, S. ;
Tabernero, J. ;
Douillard, J. -Y. ;
Andre, T. ;
Peeters, M. .
ANNALS OF ONCOLOGY, 2017, 28 (08) :1862-1868
[4]   Population-based cohort study comparing 30-and 90-day institutional mortality rates after colorectal surgery [J].
Byrne, B. E. ;
Mamidanna, R. ;
Vincent, C. A. ;
Faiz, O. .
BRITISH JOURNAL OF SURGERY, 2013, 100 (13) :1810-1817
[5]  
Casas F, 1997, CANCER, V80, P1366, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1366::AID-CNCR2>3.0.CO
[6]  
2-D
[7]  
Clark OH, 2009, J NATL COMPR CANC NE, V7, P712
[8]   Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology [J].
Crippa, Stefano ;
Partelli, Stefano ;
Belfiori, Giulio ;
Palucci, Marco ;
Muffatti, Francesca ;
Adamenko, Olga ;
Cardinali, Luca ;
Doglioni, Claudio ;
Zamboni, Giuseppe ;
Falconi, Massimo .
WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (45) :9944-9953
[9]   Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters [J].
Crippa, Stefano ;
Partelli, Stefano ;
Bassi, Claudio ;
Berardi, Rossana ;
Capelli, Paola ;
Scarpa, Aldo ;
Zamboni, Giuseppe ;
Falconi, Massimo .
SURGERY, 2016, 159 (03) :862-871
[10]   Comparative Study of Lung and Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A SEER Database Analysis of 162,983 Cases [J].
Dasari, Arvind ;
Mehta, Kathan ;
Byers, Lauren A. ;
Sorbye, Halfdan ;
Yao, James C. .
CANCER, 2018, 124 (04) :807-815